VANCOUVER, British Columbia, April 20, 2023 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a clinical stage pharmaceutical development company, is reminding its shareholders of the details of its previously announced rights offering as well as the cut off date and time for the exercise of those rights. On March 21, 2023…

Source

Previous articlePsychedelics Weekly – The Church of Psilomethoxin Controversy, Psychedelics for Long COVID, and The Growth of Bicycle Day
Next articleBetterLife To Present BETR-001 Preclinical Data at the 2023 Annual Meeting of the Society of Biological Psychiatry (SOBP) in San Diego, California